Atezolizumab

Generic Name
Atezolizumab
Brand Names
Tecentriq
Drug Type
Biotech
Chemical Formula
-
CAS Number
1380723-44-3
Unique Ingredient Identifier
52CMI0WC3Y
Background

Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.

Indication

Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions
Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
Associated Therapies
-
Clinical Trials
Related News

A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

First Posted Date
2021-08-26
Last Posted Date
2024-02-12
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
179
Registration Number
NCT05022927
Locations
🇯🇵

Chiba University Hospital, Chiba-shi, Chiba, Japan

🇯🇵

Kanagawa Cancer Center, Yokohama, Kanagawa, Japan

🇯🇵

National Cancer Center Hospital East, Kashiwa, Chiba, Japan

and more 8 locations

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

First Posted Date
2021-08-25
Last Posted Date
2024-11-18
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT05019703
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

First Posted Date
2021-08-17
Last Posted Date
2024-11-15
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
58
Registration Number
NCT05009069
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

🇨🇳

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China

🇨🇳

Zhongshan Hospital Fudan University, Shanghai, China

and more 2 locations

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC

First Posted Date
2021-08-16
Last Posted Date
2021-11-05
Lead Sponsor
Washington University School of Medicine
Registration Number
NCT05007769

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

First Posted Date
2021-08-12
Last Posted Date
2024-12-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
66
Registration Number
NCT05001880
Locations
🇺🇸

Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

Carle at The Riverfront, Danville, Illinois, United States

and more 36 locations

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

First Posted Date
2021-08-11
Last Posted Date
2024-03-15
Lead Sponsor
University of Florida
Target Recruit Count
29
Registration Number
NCT05000294
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

First Posted Date
2021-08-02
Last Posted Date
2024-03-05
Lead Sponsor
NeoImmuneTech
Target Recruit Count
83
Registration Number
NCT04984811
Locations
🇺🇸

Zangmeister Cancer Center, Columbus, Ohio, United States

🇺🇸

Tennessee Oncology - Nashville, Nashville, Tennessee, United States

🇺🇸

University of South Alabama, Mobile, Alabama, United States

and more 19 locations

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

First Posted Date
2021-07-29
Last Posted Date
2024-12-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
65
Registration Number
NCT04981509
Locations
🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

and more 9 locations

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

First Posted Date
2021-07-12
Last Posted Date
2024-05-10
Lead Sponsor
Georgetown University
Target Recruit Count
42
Registration Number
NCT04958811
Locations
🇺🇸

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

MedStar Georgetown University Hospital, Washington, District of Columbia, United States

Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN

Phase 2
Completed
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Drug: Atezolizumab
First Posted Date
2021-06-25
Last Posted Date
2024-04-25
Lead Sponsor
University Hospital, Essen
Target Recruit Count
20
Registration Number
NCT04939480
Locations
🇩🇪

University Hospital Essen, Essen, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy